Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-10-30 4:21 pm Purchase | 2023-09-29 | 13G | Bionomics Limited BNOX | Lynx1 Capital Management LP | 12,897,975 8.200% | 12,897,975 (New Position) | Filing History |
| 2023-06-02 4:56 pm Purchase | 2023-05-31 | 13G | TScan Therapeutics, Inc. TCRX | Lynx1 Capital Management LP | 5,224,600 12.200% | 5,224,600 (New Position) | Filing History |
| 2023-02-14 4:07 pm Purchase | 2022-12-31 | 13G | Cabaletta Bio, Inc. CABA | Lynx1 Capital Management LP | 2,825,976 9.700% | 465,664 (+19.73%) | Filing History |
| 2023-02-14 4:06 pm Purchase | 2022-12-31 | 13G | Passage Bio, Inc. PASG | Lynx1 Capital Management LP | 167,796 6.200% | 30,175 (+21.93%) | Filing History |
| 2023-02-14 4:06 pm Purchase | 2022-12-31 | 13G | Pieris Pharmaceuticals, Inc. PIRS | Lynx1 Capital Management LP | 70,357 7.600% | 22,550 (+47.17%) | Filing History |
| 2023-02-14 4:05 pm Purchase | 2022-12-31 | 13G | Alpine Immune Sciences, Inc. ALPN | Lynx1 Capital Management LP | 3,126,173 6.800% | 1,588,828 (+103.35%) | Filing History |
| 2023-01-23 4:28 pm Purchase | 2023-01-13 | 13G | Kinnate Biopharma Inc. KNTE | Lynx1 Capital Management LP | 2,213,178 5.000% | 2,213,178 (New Position) | Filing History |
| 2023-01-23 4:23 pm Purchase | 2023-01-13 | 13G | Pardes Biosciences, Inc. PRDS | Lynx1 Capital Management LP | 3,139,202 5.000% | 3,139,202 (New Position) | Filing History |
| 2022-12-30 4:29 pm Purchase | 2022-12-20 | 13G | Neoleukin Therapeutics, Inc. NLTX | Lynx1 Capital Management LP | 114,557 5.380% | 114,557 (New Position) | Filing History |
| 2022-10-31 4:40 pm Purchase | 2022-10-20 | 13G | Cabaletta Bio, Inc. CABA | Lynx1 Capital Management LP | 2,360,312 8.140% | 2,360,312 (New Position) | Filing History |
| 2022-10-24 4:57 pm Purchase | 2022-10-13 | 13G | Pieris Pharmaceuticals, Inc. PIRS | Lynx1 Capital Management LP | 47,808 5.100% | 47,808 (New Position) | Filing History |
| 2022-09-29 4:30 pm Purchase | 2022-09-19 | 13G | Passage Bio, Inc. PASG | Lynx1 Capital Management LP | 137,621 5.100% | 137,621 (New Position) | Filing History |
| 2022-04-22 4:26 pm Purchase | 2022-04-14 | 13G | Alpine Immune Sciences, Inc. ALPN | Lynx1 Capital Management LP | 1,537,345 5.100% | 1,537,345 (New Position) | Filing History |